Type: Oral
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis
Hematology Disease Topics & Pathways:
Research, Clinical trials, MPN, Clinical Research, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Disclosures: Masarova: PharmaEssentia: Other: Advisory Board Participant; Cogent: Other: Advisory Board Participant; MorphoSys: Other: Advisory Board Participant; GSK: Consultancy, Other: Travel support. Pemmaraju: Mustang Bio: Honoraria, Other: Travel Expenses, Research Funding; CareDx: Honoraria; Plexxikon: Research Funding; ClearView Healthcare Partners: Consultancy; Affymetrix/Thermo Fisher Scientific: Research Funding; Celgene: Honoraria, Other: Travel Expenses; Springer Science + Business Media: Honoraria; Neopharm: Honoraria; Aptitude Health: Honoraria; LFB Biotechnologies: Honoraria; Novartis: Honoraria, Research Funding; DAVA Oncology: Honoraria, Other: Travel Expenses; Incyte: Honoraria; Cellectis: Research Funding; Pacylex: Consultancy; Daiichi Sankyo: Research Funding; Protagonist Therapeutics: Consultancy; Bristol-Myers Squibb: Consultancy; Astellas: Consultancy; CTI BioPharma: Consultancy; Blueprint Medicines: Consultancy, Honoraria; Roche Molecular Diagnostics: Honoraria; Stemline Therapeutics: Honoraria, Other: Travel Expenses, Research Funding; Triptych Health Partners: Consultancy; Samus Therapeutics: Research Funding; Immunogen: Consultancy; Blueprint Medicines OncLive PeerView Institute for Medical Education: Consultancy, Other: advisory board; AbbVie: Honoraria, Other: Travel Expenses, Research Funding; ASH Committee on Communications ASCO Cancer.NET Editorial Board: Other: Leadership; Karger Publishers: Other: Licenses; National Institute of Health/National Cancer Institute (NIH/NCI): Research Funding; HemOnc Times/Oncology Times: Other: uncompensated. Kadia: Servier: Consultancy; Rigel: Honoraria; DrenBio: Consultancy, Research Funding; Regeneron: Research Funding; JAZZ: Research Funding; Amgen: Research Funding; Novartis: Honoraria; BMS: Consultancy, Research Funding; Pfizer: Research Funding; Ascentage: Research Funding; Incyte: Research Funding; ASTEX: Research Funding; AstraZeneca: Research Funding; Cellenkos: Research Funding; Sellas: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding. Bose: Pfizer: Research Funding; Ionis Pharmaceuticals: Research Funding; Blueprint: Honoraria, Research Funding; CTI Biopharma Corp: Honoraria, Research Funding; MorphSys: Honoraria, Research Funding; Kartos: Honoraria, Research Funding; Disc Medicine: Research Funding; Karyopharm: Honoraria; Cogent: Honoraria, Research Funding; GSK: Honoraria; Novartis: Honoraria; PharmaEssentia: Honoraria; AbbVie: Honoraria; Telios: Research Funding; BMS: Honoraria, Research Funding; Astellas: Research Funding; Incyte: Honoraria, Research Funding; NS Pharma: Research Funding; Promedior: Research Funding. Montalban-Bravo: Rigel: Research Funding; Takeda: Research Funding. Sadeghi: Cellenkos: Current Employment, Current equity holder in publicly-traded company. Parmar: Cellenkos: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company. Flowers: AstraZeneca: Consultancy; Bristol Myers Squibb: Consultancy; Burroughs Wellcome Fund: Research Funding; Bio Ascend: Consultancy; BostonGene: Research Funding; Eastern Cooperative Oncology Group: Research Funding; Ziopharm National Cancer Institute: Research Funding; Xencor: Research Funding; Pharmacyclics: Research Funding; Pfizer: Research Funding; Janssen Pharmaceuticals: Research Funding; Morphosys: Research Funding; Amgen: Research Funding; Allogene: Research Funding; Pharmacyclics / Janssen: Consultancy; Gilead: Consultancy, Research Funding; Genmab: Consultancy; Celgene: Consultancy, Research Funding; BeiGene: Consultancy; EMD Serono: Research Funding; Denovo Biopharma: Consultancy; Foresight Diagnostics: Consultancy, Current holder of stock options in a privately-held company; Genentech/Roche: Consultancy, Research Funding; Karyopharm: Consultancy; N-Power Medicine: Consultancy, Current holder of stock options in a privately-held company; Seagen: Consultancy; Spectrum: Consultancy; 4D: Research Funding; Acerta: Research Funding; Adaptimmune: Research Funding; Cellectis: Research Funding; Guardant: Research Funding; Iovance: Research Funding; Nektar: Research Funding; Novartis: Research Funding; Sanofi: Research Funding; Takeda: Research Funding; TG Therapeutics: Research Funding; Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research: Research Funding; Kite: Research Funding; Bayer: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding. Kantarjian: AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline,Takeda: Consultancy, Honoraria.